Zymeworks Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZYME research report →
About the company
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2.
- CEO
- Kenneth H. Galbraith
- IPO
- 2017
- Employees
- 299
- HQ
- Middletown, BC, CA
Price Chart
- Market Cap
- $1.94B
- P/E
- -19.22
- P/S
- 23.82
- P/B
- 12.01
- EV/EBITDA
- -18.11
- Div Yield
- 0.00%
- Gross Margin
- 94.42%
- Op Margin
- -140.35%
- Net Margin
- -126.33%
- ROE
- -37.79%
- ROIC
- -25.26%
- Revenue
- $105.97M · 38.87%
- Net Income
- $-81,130,000 · 33.88%
- EPS
- $-1.08 · 33.33%
- Op Income
- $-92,535,000
- FCF YoY
- 69.48%
- 52W High
- $29.75
- 52W Low
- $11.51
- 50D MA
- $25.03
- 200D MA
- $23.24
- Beta
- 1.13
- Avg Volume
- 664.63K
Get TickerSpark's AI analysis on ZYME
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | Schneider Paul R | other | 178,000 |
| May 13, 26 | Schneider Paul R | other | 119,000 |
| May 13, 26 | Schneider Paul R | other | 0 |
| Apr 9, 26 | Schayowitz Adam | other | 76,000 |
| Apr 9, 26 | Schayowitz Adam | other | 70,000 |
| Apr 9, 26 | Schayowitz Adam | other | 47,000 |
| Apr 9, 26 | Platshon Scott | other | 76,000 |
| Apr 9, 26 | Platshon Scott | other | 70,000 |
| Apr 9, 26 | Platshon Scott | other | 47,000 |
| Apr 9, 26 | Schayowitz Adam | other | 0 |
Our ZYME coverage
Recent articles, reports, and earnings notes.
No research on ZYME yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZYME report →Similar companies
Peers in the same neighborhood.